BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17440814)

  • 21. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
    Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
    Lu C; Yang D; Sabbatini ME; Colby AH; Grinstaff MW; Oberlies NH; Pearce C; Liu K
    BMC Cancer; 2018 Feb; 18(1):149. PubMed ID: 29409480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
    Kutschat AP; Hamdan FH; Wang X; Wixom AQ; Najafova Z; Gibhardt CS; Kopp W; Gaedcke J; Ströbel P; Ellenrieder V; Bogeski I; Hessmann E; Johnsen SA
    Cancer Res; 2021 Jun; 81(11):2943-2955. PubMed ID: 33436389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.
    Welsch L; Welsch T; Dovzhanskiy DI; Felix K; Giese NA; Krysko DV; Werner J
    Int J Oncol; 2012 Feb; 40(2):427-35. PubMed ID: 22020984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
    Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
    Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells.
    Ozpolat B; Akar U; Mehta K; Lopez-Berestein G
    Autophagy; 2007; 3(5):480-3. PubMed ID: 17507797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulated Electro-Hyperthermia Supports the Effect of Gemcitabine Both in Sensitive and Resistant Pancreas Adenocarcinoma Cell Lines.
    Forika G; Kiss E; Petovari G; Danko T; Gellert AB; Krenacs T
    Pathol Oncol Res; 2021; 27():1610048. PubMed ID: 34955688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway.
    Zhang X; Xu J; Yan R; Zhang Y; Hu Z; Fu H; You Q; Cai Q; Yang D
    Aging (Albany NY); 2020 Apr; 12(8):6808-6822. PubMed ID: 32291380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
    Okada Y; Takahashi N; Takayama T; Goel A
    Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
    Bosco G; Guizzon L; Yang Z; Camporesi E; Casarotto A; Bosio C; Mangar D; Chen C; Cannato M; Toniolo L; Garetto G; Nasole E; Bassi C
    Anticancer Res; 2013 Nov; 33(11):4827-32. PubMed ID: 24222119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
    Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
    Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
    Zhang X; Zhao P; Wang C; Xin B
    Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
    Zhang G; Schetter A; He P; Funamizu N; Gaedcke J; Ghadimi BM; Ried T; Hassan R; Yfantis HG; Lee DH; Lacy C; Maitra A; Hanna N; Alexander HR; Hussain SP
    PLoS One; 2012; 7(2):e31507. PubMed ID: 22363658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.